Strandberg , T E , Levinson , S L , DiNubile , M J , Jyväkorpi , S & Kivimäki , M 2022 , ' Association of plasma gelsolin with frailty phenotype and mortality among octogenarian community-dwelling men : a cohort study ' , Aging Clinical and Experimental Research , vol. 34 , no. 5 , pp. 1095-1101 . https://doi.org/10.1007/s40520-022-02083-2
Julkaisun nimi: | Association of plasma gelsolin with frailty phenotype and mortality among octogenarian community-dwelling men : a cohort study |
Tekijä: | Strandberg, Timo E.; Levinson, Susan L.; DiNubile, Mark J.; Jyväkorpi, Satu; Kivimäki, Mika |
Tekijän organisaatio: | HUS Internal Medicine and Rehabilitation Timo Strandberg / Principal Investigator Department of Medicine Clinicum Helsinki University Hospital Area HUS Helsinki and Uusimaa Hospital District Faculty of Medicine |
Päiväys: | 2022-05 |
Kieli: | eng |
Sivumäärä: | 7 |
Kuuluu julkaisusarjaan: | Aging Clinical and Experimental Research |
ISSN: | 1594-0667 |
DOI-tunniste: | https://doi.org/10.1007/s40520-022-02083-2 |
URI: | http://hdl.handle.net/10138/345171 |
Tiivistelmä: | Background Biomarkers are needed for frailty, a common phenotype often associated with muscle loss in older people. Plasma gelsolin (pGSN) is a protein largely synthesized and secreted by skeletal muscle. Aims To investigate whether pGSN could be a biomarker of the frailty phenotype and predict mortality. Methods A homogenous cohort of males (born 1919-1934, baseline n = 3490) has been followed since the 1960s. In 2010/11, frailty phenotypes by modified Fried criteria were assessed. pGSN was measured in a convenience subset (n = 469, mean age 83) and re-measured in survivors (n = 127) in 2017. Mortality through December 31, 2018 was retrieved from national registers. Regression models were used for analyses. Results Of 469 males, 152 (32.4%) were robust, 284 (60.6%) prefrail, and 33 (7.0%) frail in 2010/11. There was a graded (p = 0.018) association between pGSN (mean 58.1 ug/mL, SD 9.3) and frailty. After multivariable adjustment, higher pGSN levels were associated with lower odds of having contemporaneous phenotypic prefrailty (OR per 1 SD 0.73, 95% CI 0.58-0.92) and frailty (OR per 1 SD 0.70, 95% CI 0.44-1.11). By 2018, 179 males (38.2%) had died, and higher baseline pGSN predicted a lower 7-year mortality rate (HR per 1 SD 0.85, 95% CI 0.72-1.00). pGSN concentrations in 2010/11 and 2017 were correlated (n = 127, r = 0.34, p < 0.001). Discussion Higher baseline pGSN concentrations were associated with a persistently robust phenotype and lower mortality rate over 7 years in a cohort of octogenarian males with high socioeconomic status and may be a promising laboratory biomarker for the development of a frailty phenotype. |
Avainsanat: |
Biomarker
Prefrailty Sarcopenia MARKER MUSCLE 3111 Biomedicine 3121 General medicine, internal medicine and other clinical medicine |
Vertaisarvioitu: | Kyllä |
Tekijänoikeustiedot: | cc_by |
Pääsyrajoitteet: | openAccess |
Rinnakkaistallennettu versio: | publishedVersion |
Latausmäärä yhteensä: Ladataan...
Tiedosto(t) | Koko | Formaatti | Näytä |
---|---|---|---|
Strandberg2022_ ... ionOfPlasmaGelsolinWit.pdf | 490.5KB | Avaa tiedosto |